NIH: Public Servant or Private Marketer? Wed, 22 Dec 2004 David Willman of the Los Angeles Times provides an important reminder that the FDA is not the only government healthcare agency to have betrayed the public trust and lost its credibility. While the FDA has lent its seal of approval…
Chief of VA Research Departs amidst allegations of misconduct, financial indiscretion – BNA Sat, 13 Dec 2003 The Bureau of National Affairs (BNA) reports that Dr. Nelda Wray, chief of research at the Veterans Affairs, “leaves office as the VA Inspector General prepares to release results of an investigation into…
How to earn promotions in pharmaceutical industry Tue, 6 Sep 2005 In the world of pharmaceuticals, careers are made by marketing the worst products that cause the greatest harm. Contact: Vera Hassner Sharav 212-595-8974 XenoPort Appoints Gary D. Tollefson, Former Lilly Executive, to Board Company Snapshot: XNPThttp://www.xenoport.com SANTA CLARA, Calif.,…
FDA’s Lethal Weakness Requires More than Committees Sun, 7 Nov 2004 Bloomberg News reports that New York State Attorney General Eliot Spitzer requested information from Pfizer about the promotion of some of its drugs for unapproved uses – the recalled diabetes drug, Rezulin and the antidepressant, Zoloft were named. In…
Not-So-Public-Relations: Drug Industry & Bioethics – is it casuistry or sophistry? Fri, 19 Dec 2003 Carl Elliott is a clear eyed academic who teaches bioethics at the University of Minnesota . He is currently a visiting associate professor at School of Social Sciences at the Institute for Advanced Study at Princeton….
AHRP InfoMail Return to Home Page Return to InfoMail Media Coverage List MediaCoverage News Stories on Human ResearchProtection andCommentary by Vera Hassner Sharav February 19a, 2002 INSANE PSYCHIATRY: AProfession Run Amok FYI Nicholas Regush is an award winning reporter on medicaland scientific issues. For 6 years he was the medical…
NY Times Does it Again – Drug Advertisers Get Front Page Coverage to Boost SSRI Market Wed, 2 Jun 2004 The New York Times saw fit to print a report about preliminary, unpublished findings of a study whose authors claim to have “found that Prozac helps teenagers overcome depression far…
4 compelling reasons against Mental Health Parity Fri, 12 Sep 2003 Compelling reasons NOT to approve insurance parity for mental health services come from the following recent reports suggesting that mental health services and treatments have often done more damage than good. Until psychiatry and mental health service providers develop…
Alliance for Human Research Protection in the Press Feb 17, 2005: FDA Critics Slam Plan for Safety Reform – Nature “This is smoke and mirrors and musical chairs,” says Vera Sharav, president of the New York-based Alliance for Human Research Protection. “They will be using the very same officials that…
Antidepressant Makers Withhold Data on Children – Washington Post Thu, 29 Jan 2004 A front page article in The Washington Post addresses the key issue undermining public health and safety. Drug companies conceal unfavorable clinical trial findings: the tests failed to demonstrate that antidepressants are either safe or beneficial for…
Leading Antipsychotic Drugs Come Under New Scrutiny – NYT Tuesday, May 20, 2003 A front page article in The New York Times reveals that the pillars of American psychiatry–including Dr. Jeffrey Lieberman, Dr. John Kane, Dr. William Carpenter–are acknowledging that evidence is lacking to support the claims that the new…
October 1, 2001 Text of AHRP Amicus Brief filed with the Maryland Court of Appeals in support of the Court’s ruling against Kennedy Krieger Institute for exposing children to lead poison in an experiment. The Court of Appeals Decision Validates AHRP’s Stand Against Using Children in Harmful Research Experiments. ___________________________________________________…
